Key Takeaways
A class-action lawsuit was filed against Immutep Limited (NASDAQ: IMMP), alleging the company and its officers violated federal securities laws by making misleading statements about a key clinical trial. The lawsuit follows an 82.6% collapse in the company's stock price.
The legal action, announced by the law firm Bronstein, Gewirtz & Grossman, LLC, seeks to recover damages for investors who purchased Immutep securities between March 24, 2025, and March 12, 2026. The complaint centers on allegedly false and misleading statements concerning the efficacy of the TACTI-004 Phase III clinical trial for its drug eftilagimod alfa.
The situation came to a head on March 13, 2026, when Immutep announced that the trial's Independent Data Monitoring Committee (IDMC) recommended discontinuing the study for futility. Following the news, Immutep's American Depositary Receipt (ADR) price fell $2.28, closing at $0.48 per ADR.
The lawsuit alleges that the company concealed adverse facts about the trial's viability. Another law firm, Faruqi & Faruqi, LLP, has also been investigating and reminded investors of a July 6, 2026, deadline to seek the role of lead plaintiff. The discontinuation of the trial for "futility" suggests the available data showed the drug was unlikely to meet its primary endpoints.
The sharp stock decline and subsequent legal actions represent a significant setback for Immutep, potentially exposing the company to substantial financial penalties. For investors, the decline has erased significant value, and the upcoming legal proceedings will be closely watched for any potential recovery.
This article is for informational purposes only and does not constitute investment advice.
